Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11617597 | 0.77 | ALDH1A1 (0.41) | GPR84 | |
| SCHEMBL11376319 | 0.72 | GPR84 (0.75) | GPR84TYMP | |
| SCHEMBL8709983 | 0.72 | GPR84 (0.77) | GPR84TYMP | |
| SCHEMBL27172466 | 0.70 | GPR84 (0.56) | GPR84TYMP | |
| SCHEMBL7967579 | 0.69 | UNG (0.58) | — | |
| SCHEMBL7563397 | 0.69 | GPR84 (0.73) | GPR84TYMP | |
| SCHEMBL12219726 | 0.69 | GPR84 (0.90) | GPR84TYMP | |
| SCHEMBL28298641 | 0.68 | KDM4C (0.46) | GPR84 | |
| SCHEMBL3261738 | 0.68 | GPR84 (1.00) | GPR84TYMP | |
| SCHEMBL8974784 | 0.67 | GPR84 (0.50) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877765-B2 | Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-11-04 | — | — | US | disclosed |
| US-20100056549-A1 | HIGHLY SOLUBLE PYRIMIDO-DIONE-QUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2007146375-A2 | HIGHLY SOLUBLE PYRIMIDO-DIONE-QUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-12-21 | — | — | WO | disclosed |
| US-7253176-B1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-07 | — | — | US | disclosed |
| EP-0956855-B1 | Immunosuppressive effects of 8 substituted xanthine derivatives | LEUVEN K U RES & DEV (BE) | 2003-03-12 | — | — | EP | disclosed |
| US-6177437-B1 | VIRICIDES | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER | 2001-01-23 | — | — | US | disclosed |
| EP-0956855-A1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. Leuven Research & Development (BE) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056549-A1 | HIGHLY SOLUBLE PYRIMIDO-DIONE-QUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | DPYD, DHFR, DHPS | GPR84 1025/4885TYMP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.